Company Overview and News
EDMONTON, Alberta, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI) is pleased to announce that it has received its Controlled Drugs and Substances Licence, also known as a Dealer’s Licence (the “Licence”), from Health Canada’s Office of Controlled Substances for its Manufacturing Facility located at 4035 – 101 NW Street, Edmonton, Alberta.
ACB ACBFF RTI
When members of my anti-pharma, anti-tobacco, anti-alcohol stock club suggested investing in cannabis several months ago, I was surprised. So, I promptly found a good reason to stall.
STZ.B WEED RTI PMD RDDTF STZ CGC SMG
EDMONTON, Alberta, Sept. 18, 2018 (GLOBE NEWSWIRE) -- At the request of IIROC, Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI) wishes to confirm that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity.
2018-08-28 globenewswire - 1
EDMONTON, Alberta, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI) is pleased to announce financial results for the first fiscal quarter ended June 30, 2018 and provide a corporate update. The Financial statements are available on www.SEDAR.com.
ACB ACBFF RTI
2018-07-06 globenewswire - 1
EDMONTON, Alberta, July 06, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture:RTI), is encouraged by Health Canada’s recently introduced Cannabis Regulations and Industrial Hemp Regulations in accordance with the Cannabis Act – a new legal framework that puts in place a comprehensive public health approach to cannabis in Canada.
ACB ACBFF RTI
On June 19, 2018, the Canadian Senate passed The Cannabis Act 52 to 29. The rest of the approval process will be completed before the end of the week.
SNNVF KHRNF ACBFF RTI DTK CGC GSK LXX TWMJF ACB WEED RDDTF OGRMF OGI LXRP
EDMONTON, Alberta, June 12, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture:RTI) is pleased to announce that it has made a submission to the U.S. Food and Drug Administration (the “FDA”) to consider the Company’s proprietary technology as a method to reduce nicotine levels in tobacco.
Edmonton, AB, May 22, 2018 (GLOBE NEWSWIRE) -- Aurora Cannabis Inc. (“Aurora” or the “Company”) (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and CTT Pharmaceutical Holdings Inc. ("CTT") (US-OTC: CTTH) today announced that Aurora is acquiring an initial 9.14% ownership interest in CTT via way of a non-brokered private placement in the form of a US$1 million 5% convertible debenture. The agreement includes an issuance of warrants enabling Aurora to increase ownership to 42.
ACB CTTH ACBFF RTI TXCX CNGGF
EDMONTON, Alberta, May 03, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture:RTI) is pleased to announce it has completed its previously announced real estate acquisitions (please see the Company’s April 18, 2018 news release).
ACB ACBFF RTI
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to TSXV:RTI / Radient Technologies Inc on message board site Silicon Investor.